Voyager Therapeutics (VYGR) Tops Q1 EPS by 287c

Voyager Therapeutics (NASDAQ: VYGR) reported Q1 EPS of $2.94, $2.87 better than the analyst estimate of $0.07. Revenue for the quarter came in at $150.48 million versus the consensus estimate of $10.04 million.

For earnings history and earnings-related data on Voyager Therapeutics (VYGR) click here.

You May Also Be Interested In

• IBM plunges 19% as memory capex squeeze derails Q2 earnings
• Goldman Sachs (GS) Tops Q2 EPS by $6.60, Beats on Revenue
• Fastenal (FAST) Reports In-Line Q2 EPS, Beats on Revenue